Several recent books have criticized the pharmaceutical industry for developing too many "follow-on" or "me-too" drugs--a name given to drugs that work the same way as pioneering drugs that create a new class of treatments. Do follow-on drugs raise costs while diverting R&D funds from true innovation, and should the...